YKT6

Across TCGA pan-cancer cohorts, YKT6 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of YKT6’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where YKT6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types YKT6 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

HNSC, BLCA, and STAD are the cancer types where YKT6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in YKT6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	IV	+1.238	<.001	12	view →
BLCA	All	All	+0.813	<.001	11	view →
STAD	All	II,III,IV	+0.885	<.001	10	view →
LIHC	Female	II,III,IV	+1.676	<.001	9	view →
LUAD	Male	III,IV	+1.193	<.001	9	view →
KIRP	Male	II,III,IV	+0.699	<.001	9	view →
LUSC	Male	III,IV	+1.250	<.001	8	view →
COAD	Male	II,III,IV	+0.435	<.001	8	view →
UCEC	All	II,III,IV	+0.846	<.001	6	view →
BRCA	All	III,IV	+0.683	<.001	6	view →
CHOL	Male	All	+2.935	<.001	5	view →
THCA	Male	III,IV	−0.462	.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

YKT6–HNSC

Open the HNSC breakdown →